PD-L1 evaluation with DAKO and BIOCARE antibody for immunotherapy; Same coin different faces

P. Zarogoulidis (tHESSALONIKI, Greece), K. Porpodis (ttHESSALONIKIH, Greece), D. Xatzibougias (ThesaalonikittHESSALONIKIH, Greece), T. Tsiouda (ThessalonikiThesaalonikittHESSALONIKIH, Greece), D. Daniilidis (KavalaThessalonikiThesaalonikittHESSALONIKIH, Greece)

Source: International Congress 2019 – Diagnosis of lung cancer
Session: Diagnosis of lung cancer
Session type: Thematic Poster
Number: 3072
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Zarogoulidis (tHESSALONIKI, Greece), K. Porpodis (ttHESSALONIKIH, Greece), D. Xatzibougias (ThesaalonikittHESSALONIKIH, Greece), T. Tsiouda (ThessalonikiThesaalonikittHESSALONIKIH, Greece), D. Daniilidis (KavalaThessalonikiThesaalonikittHESSALONIKIH, Greece). PD-L1 evaluation with DAKO and BIOCARE antibody for immunotherapy; Same coin different faces. 3072

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019


The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma
Source: Eur Respir J 2001; 18: 45-52
Year: 2001



Reversing the suppression of T-cells: the role of monoclonal antibodies
Source: International Congress 2015 – Stop immune tolerance in lung cancer!
Year: 2015



Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021



Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody
Source: ERS Lung Science Conference 2021
Year: 2021

A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study
Source: Eur Respir J 2007; 30: Suppl. 51, 622s
Year: 2007

Differences in the response to treatment with monoclonal antibodies according to age
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020


Monitoring of monoclonal antibody therapy with a new recovery ELISA assay technique (R-ELISA®)
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010

Antigen exposure and IgG antibody response in pigeon fanciers
Source: Eur Respir J 2005; 26: Suppl. 49, 374s
Year: 2005

Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011

A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all?
Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease
Year: 2020


Specific monoclonal antibody to detect the C-terminal peptide of alpha1-antitrypsin: clinical importance
Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions
Year: 2019

Rapid detection of Mycoplasma pneumoniae IgM antibodies using ImmunoCard Mycoplasma kit compared with complement fixation (CF) tests and clinical application
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012

Omalizumab, an anti-immunoglobin E antibody, is not associated with an increased risk of immunological reactions
Source: Eur Respir J 2002; 20: Suppl. 38, 108s
Year: 2002

MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012

Massive monoclonal expansion of CD4 T-cells specific for a Mycobacterium tuberculosis ESAT-6 peptide
Source: Eur Respir J 2012; 40: 152-160
Year: 2012



Management of severe allergic asthma in the UK: Which monoclonal antibody would you choose?
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011